Athersys found using ticker (ATHX) have now 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 9 and 5 with the average target price sitting at 6.8. With the stocks previous close at 1.75 this would imply there is a potential upside of 288.6%. The day 50 moving average is 1.82 while the 200 day moving average is 2.14. The company has a market cap of $356m. You can visit the company’s website by visiting: http://www.athersys.com
Athersys, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys was founded in 1995 and is headquartered in Cleveland, Ohio.